Related Experiment Video

Updated: Jun 21, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies

Francisco J Hernandez-Ilizaliturri1, Myron S Czuczman

  • 1Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

Oncology (Williston Park, N.Y.)
|July 25, 2009
PubMed

Insights

Novel agents offer new treatment options for diffuse large B-cell lymphoma (DLBCL) patients ineligible for high-dose chemotherapy. Research focuses on targeted therapies and biomarkers for improved patient outcomes.

Area of Science:

  • Oncology
  • Biotechnology
  • Hematology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) presents treatment challenges, especially for patients ineligible for high-dose chemotherapy.
  • Advances in biotechnology are yielding novel biomarkers for DLBCL categorization and risk stratification.
  • Targeted therapies are emerging to address key pathways in DLBCL initiation, growth, and progression.

Purpose of the Study:

  • To review current and emerging treatment options for relapsed/refractory DLBCL.
  • To highlight therapeutic challenges, particularly for patients previously treated with rituximab.
  • To discuss the integration of novel agents and biomarkers in DLBCL management.

Main Methods:

  • Literature review of recent clinical trials and research in DLBCL.
  • Analysis of novel agents targeting specific cellular pathways in DLBCL.
  • Examination of biomarker applications in DLBCL patient stratification.

Main Results:

  • Novel agents demonstrate promising activity and manageable toxicity in DLBCL treatment.
  • Biomarker development aids in categorizing DLBCL subtypes and stratifying patient risk.
  • Early clinical data for novel agents in DLBCL are encouraging.

Conclusions:

  • Patients with DLBCL ineligible for high-dose chemotherapy have expanding treatment options.
  • Novel agents and biomarkers represent significant progress in managing DLBCL.
  • Addressing challenges in rituximab-exposed patients is crucial for future DLBCL therapy.

More Related Videos

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...